ArticleScientific reports2025
Transcriptomic profiling to investigate the therapeutic potential and medicinal properties of Momordica cymbalaria.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Momordica cymbalaria (Athalakkai), a medicinally important Cucurbitaceae species, is widely used in traditional medicine due to its antidiabetic, anticancer, and antimicrobial properties. However, the molecular mechanisms underlying its therapeutic potential remain poorly understood. Here, we present a comprehensive transcriptome analysis of M. cymbalaria using Illumina HiSeq 4000 sequencing of leaf, fruit, and seed tissues. De novo assembly generated 450,785 contigs (N50: 460 bp) with 72,283 annotated unigenes. Our key findings reveal pivotal genes involved in the biosynthesis of pharmaceutically relevant secondary metabolites, including terpenoids, steroids, and isoquinoline alkaloids. Notably, enzymes such as hydroxymethylglutaryl-CoA reductase, cycloeucalenol cycloisomerase, and tyrosine aminotransferase were recognized as central to these pathways. Gene Ontology (GO) analysis has classified the transcripts into molecular functions (181,789), biological processes (242,672), and cellular components (126,350). We further characterized 5,025 transcription factors, with bHLH, MYB, and WRKY families being prominently associated with secondary metabolism regulation. Tissue-specific expression patterns were identified and validated by qRT-PCR, showing eminent metabolic activity in leaves and fruits compared to seeds. This study provides the first genomic resource for M. cymbalaria, offering molecular insights into its medicinal properties and facilitating future biotechnological applications in drug discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.